353-23 | A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD-1 Study

Trial Number

353-23

Participant Age Range

6 years to 17 years

Participant Gender

Any

Enrolling Participants

Yes

Overview

“A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine – The REBUILD-1 Study”

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo (an inactive substance) in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.